TrialClinical cancer research : an official journal of the American Association for Cancer Research2026

A Phase 2 Trial of RANKL Antibody, Denosumab, in Two Cohorts of Patients with Recurrent/Refractory Osteosarcoma, a Report from the Children's Oncology Group.

Katherine A Janeway et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.